Purple Biotech (PPBT) said Tuesday it is advancing its drug candidate NT219 into a phase 2 clinical trial aimed at overcoming tumor resistance in therapies for recurring metastatic squamous cell cancer of the head and neck.
The study will evaluate the safety and efficacy of NT219 in combination with standard therapies like pembrolizumab and cetuximab, focusing on overcoming the resistance mechanisms tumors develop against such treatments, the company said.
Purple Biotech's shares were up over 10% in recent Tuesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。